Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

By Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yang Li. 2023

Subfields: Immunology, Oncology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “Standard treatment modalities—surgery, radiotherapy, and chemotherapy—frequently yield limited success, emphasizing the need for novel, targeted therapeutic strategies [6–8].”
• Impact of T Cell Exhaustion and Stroma Senescence on Tumor Cell Biology and Clinical Outcome of Head and Neck Squamous Cell Carcinomas (2024, unknown): “In melanoma, the dual LAG-3 and PD-1 inhibitor Opdualag was already approved by the FDA for treating unresectable or metastatic disease in adults and children [39,40].”